Event Date/Time: Jul 07, 2010 End Date/Time: Jul 08, 2010
Report as Spam


SMi's 5th Annual ADMET: Translating research into clinical outcomes will bring you up to date with the latest developments, technologies and techniques that are in use across the industry and look towards the future.

By attending this conference, you will learn:

• How to effectively integrate ADMET optimisation into drug discovery to reduce attrition rates from AstraZeneca
• Strategies for predicting drug-drug interactions arising from CYP450 inhibition from Pfizer
• How to develop a mechanism-based PK/PD model from Eli Lilly
• The application of High Content Analysis for predictive cytotoxicity testing & preclinical toxicity biomarkers from University College Dublin
• Tools and strategies to consider in characterising and investigating hepatotoxicity from Genetech
• What the emerging in vitro toxicity assays are and the role of stem cells in assessing human toxicology from Roche
• Case studies demonstrating the benefits of evaluating PK in early stage drug development from Merck

The conference will provide a look at how the big names in the pharma industry are approaching ADMET. With a case study focus and presentations from companies including Novartis, AstraZeneca, Pfizer, Eli Lilly, Genentech, MSD, Merck & Co., Roche, Gedeon Richter and more along with distinguished representatives from top academic organisations this conference promises to provide an intimate environment for benchmarking against industry leaders and networking.

Featured Presentations:

• Building hypotheses in lead selection and optimisation
Bernard Faller, Director of Metabolism & Pharmacokinetics / in-vitro ADME, Novartis
• ADME Optimisation in Early- and Late-Phase Drug Discovery
Gerhard Gross, Global Discipline Leader ADME, AstraZeneca
• In Vitro and In Vivo Approaches for Assessing the Potential for Drug Induced Liver Injury
Donna Dambach, Director, Investigative Safety Assessment, Genentech
• Emerging In Vitro Toxicity Assays and the Role of Stem Cells in Assessing Human Toxicology
Claudia McGinnis, Group Head, In Vitro Toxicology, Roche

Conference Sessions Include:

• Targeting Drugs for the Brain
• Vinblastine Treated CaCo-2 Culture as a Drug Penetration Model - An Added Value Model of Drug Penetration
• Structure-based ADMET Studies – Challenges and Opportunities
• Drug Transporter Assays in Discovery
• The Utility and Application of TDI Screens in Early Discovery DMPK
• System-dependent inhibition of cytochrome P450 (CYP) enzymes – Common Misconceptions and errors
• Integrating Predictive Toxicology Model Development
• Segregation of Genotoxic Compounds
• Mechanisms of Human (Hepato)Toxicity
• Is There Too Much (Hot) Air in Genetic Toxicity Assessment?


Additional Information

Plus a half day post conference workshop: Current Perspectives and Approaches on the Application of Computational Modelling in PK, PK/PD and Toxicity Prediction Hosted by: Dr. Barry Hardy, Director, Community of Practice & Research Activities and OpenTox Project Coordinator, Douglas Connect Workshop faculty: Dr. Gerhard Gross, Global Discipline Leader ADME, AstraZeneca 8.30 – 1.00pm – 9th July 2010, Crowne Plaza St James Hotel, London, UK